Proscia Grows with 2.4 Million Patients Diagnosed via AI Pathology Platform
Proscia, a company specializing in AI-enabled pathology solutions, reported significant growth in 2024, driven by an increasing demand for enterprise pathology platforms.
Proscia’s Concentriq platform saw increased adoption among clinical laboratories and life sciences organizations. The company announced that 2.4 million patients were diagnosed using Concentriq in 2024, with expectations of over 8 million in 2025. This growth is bolstered by collaborations with partners like Agilent Technologies and Siemens Healthineers. Additionally, pharmaceutical companies responsible for a significant share of the industry’s best-selling drugs have integrated the platform into their operations.
See also: The Rising Role of AI-enabled Digital Pathology in Drug Discovery
Proscia expanded its capabilities in October 2024 with the release of Concentriq Embeddings and the Proscia AI Toolkit, providing tools to simplify AI model development in digital pathology. These additions enabled life sciences teams to generate embeddings from pathology images using foundation models like DINOv2, PLIP, ConvNext, and CTransPath, facilitating biomarker discovery, clinical trial optimization, and diagnostic development. The platform’s integration with Proscia’s real-world data repository, which now includes over 10 million de-identified pathology images, allows researchers to link histological and molecular data for a range of studies.
During pilot programs with a leading CRO and a top pharmaceutical company (internal case study), Concentriq Embeddings accelerated AI development by 13x, enabling the creation of 80 AI-based breast cancer biomarker models in under 24 hours.
The company’s real-world data segment has also grown substantially, with a tenfold increase in activity supported by the addition of 150,000 new records each month.
Cover photo: Proscia's RWD screen, Proscia
Topics: AI & Digital
